OXiGENE Announces Completion Of Enrollment Of ZYBRESTAT(R) Phase 2 Ovarian Cancer Trial

SOUTH SAN FRANCISCO, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that enrollment has been completed in a randomized Phase 2 clinical trial testing the combination of ZYBRESTAT® (fosbretabulin; CA-4P) plus bevacizumab to treat patients with advanced ovarian cancer. This trial, GOG-0186I, is being conducted by the Gynecologic Oncology Group (GOG) under the sponsorship of Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). This is the first and currently the only randomized trial to test an antiangiogenic therapeutic agent combined with a vascular disrupting agent in ovarian cancer, without including any cytotoxic chemotherapy. The fosbretabulin tromethamine is being provided to CTEP under a Cooperative Research and Development Agreement (CRADA) with OXiGENE and the bevacizumab is being provided under a CRADA with Genentech, Inc.

"We are pleased that this study has reached this important milestone, and look forward to final results and continuing to collaborate with GOG and Genentech, as the results from this clinical trial will inform our understanding of the therapeutic potential of combining these two anti-vascular approaches," said Peter Langecker, M.D., Ph.D., OXiGENE Chief Executive Officer. "We believe that there is a strong scientific rationale for this combination, as well as compelling preclinical and Phase 1 data that support this approach. Both Avastin and ZYBRESTAT target the tumor vasculature, but they work very differently and in complementary ways. ZYBRESTAT targets and destroys the established vasculature that supplies blood to the tumor, and therefore targets the core of the tumor to deprive it of the oxygen it needs to grow. Avastin is designed to target the newly forming vasculature that forms primarily on the outside of the tumor as tumor growth occurs. Combined, we believe they will result in a more significant reduction in blood flow that can starve and kill the tumor than with either drug alone."

If you liked this article you might like

OXiGENE (OXGN) Stock Gains on Positive FDA Feedback for Cancer Treatment Trials

Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta

Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data

Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta

3 Biotech Stocks Under $10 in Breakout Territory